Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.90 +0.21 (+1.34%)

Streaming Delayed Price Updated: 10:04 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

October 11, 2023

Via Benzinga

A Look Into Takeda Pharmaceutical Inc's Price Over Earnings ↗

October 04, 2023

Via Benzinga

Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years

October 03, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories ↗

October 03, 2023

Benzinga

Via Benzinga

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

September 25, 2023

Via Benzinga

Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial ↗

October 03, 2023

Following discussions with the FDA, Takeda Pharmaceutical Co Ltd (NYSE: TAK) will voluntarily withdraw Exkivity (mobocertinib)

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 02, 2023

Via Benzinga

Takeda Provides Update on EXKIVITY® (mobocertinib)

October 02, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Can Japan's Economy Continue To Blossom If Bank of Japan Raises Rates? Apparently So. ↗

October 02, 2023

Amid an economic climate of high interest rates in the US and a slumber among China stocks led by a downturn in the property market, Japan’s economy lies in stark contrast to the antipathy that...

Via Benzinga

Topics Economy

(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗

September 08, 2023

Via Benzinga

Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris ↗

August 24, 2023

Via The Motley Fool

2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now ↗

August 23, 2023

These two high-yield dividend stocks are attractive buys right now.

Via The Motley Fool

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

September 29, 2023

— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —

From HUTCHMED (China) Limited

Via GlobeNewswire

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

September 27, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

How Is The Market Feeling About Takeda Pharmaceutical? ↗

August 17, 2023

Via Benzinga

(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗

August 01, 2023

Via Benzinga

Morphic Therapeutic's Stock Plunges On Monday - Here's Why? ↗

September 25, 2023

Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results...

Via Benzinga

The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days ↗

September 25, 2023

The company is working on a treatment for ulcerative colitis. But competitive questions linger.

Via Investor's Business Daily

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

September 25, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Top 4 Health Care Stocks That Should Keep You Up At Night ↗

September 21, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)

September 20, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now? ↗

September 18, 2023

When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to...

Via Benzinga

Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan ↗

September 13, 2023

JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the...

Via Benzinga

Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries

September 13, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

September 13, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

September 11, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan ↗

August 28, 2023

ImmunoGen, Inc. (NASDAQ: IMGN) inked pacts with Takeda Pharmaceutical Company Limited (NYSE: TAK) to develop and

Via Benzinga

Why Are Poseida Therapeutics Shares Moving Higher Today? ↗

August 07, 2023

Poseida Therapeutics Inc (NASDAQ: PSTX) shares are trading higher after the company received a $50 million strategic investment by Astellas Pharma Inc (OTC: ALMPY) (OTC:

Via Benzinga

Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products

July 27, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

July 26, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.